US trade tariffs and the potential impact on pharma supply chains
As the pharma sector braces for sector-specific tariffs from President Trump, what could the impact look like on supply chains and drug prices?
In Association With Datwyler
Putting quality first in the pharma supply chain
How the GLP-1 receptor agonist market could hit $168bn by 2033
No nitrosamines: How parenteral packaging is evolving to meet today’s E&L challenges
The next phase for mRNA: Looking beyond COVID-19
Why small particles matter: Manufacturing and micro-material contamination
Five years of FirstLine in the United States
